Jonathan I. Izawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan I. Izawa has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Joseph L. Chin
†Departments of Surgery & Oncology, Divisions of Urology & Surgical Oncology, The University of Western Ontario Schulich School of Medicine & Dentistry, London, ON
8 shared publications- Venu Chalasani
Departments of Surgery & Oncology, Divisions of Urology & Surgical Oncology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON
5 shared publications - Wassim Kassouf
Department of Surgery, McGill University, Montreal, Quebec, Canada
5 shared publications - Joseph L. Chin
Division of Urology, Department of Surgery, Western University, London, Canada
4 shared publications - Yves Fradet
Department of Urology, Laval University, Quebec, QC, Canada
4 shared publications Larry Stitt
Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON
3 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (5)
Endoscopic Closure of a Postablation Colorenal Fistula Using a Through-The-Scope Helical Suturing System
Colorenal fistulae are a rare complication after percutaneous ablation of renal cell carcinoma tumors. Through-the-scope suturing (TTSS) is becoming increasingly used in the repair of gastrointestinal defects, including fistulae and perforations. We describe a technically and clinically successful case of endoscopic closure of a left-sided colorenal fistula using TTSS. TTSS is safe, relatively low cost, and easy to learn. It can be considered as an initial therapy in the closure of colonic fistulae, before proceeding to surgery, which carries significantly higher morbidity.
- 1 May 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (5)
Open AccessEndoscopic Closure of a Postablation Colorenal Fistula Using a Through-The-Scope Helical Suturing System
Colorenal fistulae are a rare complication after percutaneous ablation of renal cell carcinoma tumors. Through-the-scope suturing (TTSS) is becoming increasingly used in the repair of gastrointestinal defects, including fistulae and perforations. We describe a technically and clinically successful case of endoscopic closure of a left-sided colorenal fistula using TTSS. TTSS is safe, relatively low cost, and easy to learn. It can be considered as an initial therapy in the closure of colonic fistulae, before proceeding to surgery, which carries significantly higher morbidity.
- Open Access
- 8 December 2020
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 78-85
Primary Mediastinal Germ Cell Tumors—The University of Western Ontario Experience
Extragonadal germ cell tumors account for 2–5.7% of germ cell tumors (GCTs). Of these, primary mediastinal GCTs (PMGCTs) are responsible for 16–36% of cases. Given the rarity of these tumors, specific treatment strategies have not been well defined. We report our experience in treating these complex patients. In total, 318 men treated at our institution with chemotherapy for GCTs between 1980 and 2016 were reviewed. PMGCT was defined as clinically diagnosed mediastinal GCT with no evidence of testicular GCT (physical exam/ultrasound). We identified nine patients diagnosed with PMGCT. All patients presented with an anterior mediastinal mass and no gonadal lesion; four patients also had metastatic disease. Median age at diagnosis was 30 years (range, 14–56) and median mass size at diagnosis was 9 cm (range, 3.4–19). Eight patients had non-seminoma and one had pure seminoma. All patients received cisplatin-based chemotherapy initially. Surgical resection was performed in four patients; three patients had a complete resection and one patient was found to have an unresectable tumor. At a median follow-up of 2 years (range, 3 months–28 years) six patients had progressed. Progression-free survival was short with a median of 4.1 months from diagnosis (range 1.5–122.2 months). Five patients died at a median of 4.4 months from diagnosis. One and 5-year overall survivals were 50% and 38%, respectively. PMGCT are rare and aggressive. Our real-life Canadian experience is consistent with current literature suggesting that non-seminoma PMGCT has a poor prognosis despite prompt cisplatin-based chemotherapy followed by aggressive thoracic surgery.
- 8 December 2020
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 78-85
Open AccessPrimary Mediastinal Germ Cell Tumors—The University of Western Ontario Experience
Extragonadal germ cell tumors account for 2–5.7% of germ cell tumors (GCTs). Of these, primary mediastinal GCTs (PMGCTs) are responsible for 16–36% of cases. Given the rarity of these tumors, specific treatment strategies have not been well defined. We report our experience in treating these complex patients. In total, 318 men treated at our institution with chemotherapy for GCTs between 1980 and 2016 were reviewed. PMGCT was defined as clinically diagnosed mediastinal GCT with no evidence of testicular GCT (physical exam/ultrasound). We identified nine patients diagnosed with PMGCT. All patients presented with an anterior mediastinal mass and no gonadal lesion; four patients also had metastatic disease. Median age at diagnosis was 30 years (range, 14–56) and median mass size at diagnosis was 9 cm (range, 3.4–19). Eight patients had non-seminoma and one had pure seminoma. All patients received cisplatin-based chemotherapy initially. Surgical resection was performed in four patients; three patients had a complete resection and one patient was found to have an unresectable tumor. At a median follow-up of 2 years (range, 3 months–28 years) six patients had progressed. Progression-free survival was short with a median of 4.1 months from diagnosis (range 1.5–122.2 months). Five patients died at a median of 4.4 months from diagnosis. One and 5-year overall survivals were 50% and 38%, respectively. PMGCT are rare and aggressive. Our real-life Canadian experience is consistent with current literature suggesting that non-seminoma PMGCT has a poor prognosis despite prompt cisplatin-based chemotherapy followed by aggressive thoracic surgery.
- 16 October 2015
- Published by Springer Nature in World Journal of Urology
- Vol. 34 (1) , 19-24
Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy
Ileal conduit (IC) is the most frequent urinary diversion (UD) performed after radical cystectomy (RC). We reviewed the literature to investigate the factors influencing the choice of this diversion and its complications. A literature search (PubMed) was performed for all English language publications on UDs performed for treatment of bladder cancer from 1950 to 2015. The literature review was focused on studies reporting outcome of IC and its comparison with other types of UDs. IC is the most common UD performed in elderly patients undergoing RC for bladder cancer. Long-term studies looking at the change in renal function after UD report a universal decline in the glomerular filtration rate; however, this decline in renal function is the least for IC. There is a significant morbidity of RC (20–56 %), which can be attributed to patient factors, surgical technique and hospital volume. Modern concepts of bowel preparation, postoperative nutrition, early enteral feeding and involvement of stoma therapists have helped improve the outcomes. The quality of life is preserved, and in many including elderly, it may be improved with IC UD. IC is the most commonly performed UD following radical cystectomy. It is associated with acceptable morbidity and has the lowest reoperation rates as compared to continent diversion. It is also the procedure of choice for most patients’ elderly patients as well as patients with limited dexterity, poor motivation, anatomical restrictions and poor renal function. Studies measuring HRQOL report excellent patient acceptability, especially in the elderly population.
- 16 October 2015
- Published by Springer Nature in World Journal of Urology
- Vol. 34 (1) , 19-24
Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy
Ileal conduit (IC) is the most frequent urinary diversion (UD) performed after radical cystectomy (RC). We reviewed the literature to investigate the factors influencing the choice of this diversion and its complications. A literature search (PubMed) was performed for all English language publications on UDs performed for treatment of bladder cancer from 1950 to 2015. The literature review was focused on studies reporting outcome of IC and its comparison with other types of UDs. IC is the most common UD performed in elderly patients undergoing RC for bladder cancer. Long-term studies looking at the change in renal function after UD report a universal decline in the glomerular filtration rate; however, this decline in renal function is the least for IC. There is a significant morbidity of RC (20–56 %), which can be attributed to patient factors, surgical technique and hospital volume. Modern concepts of bowel preparation, postoperative nutrition, early enteral feeding and involvement of stoma therapists have helped improve the outcomes. The quality of life is preserved, and in many including elderly, it may be improved with IC UD. IC is the most commonly performed UD following radical cystectomy. It is associated with acceptable morbidity and has the lowest reoperation rates as compared to continent diversion. It is also the procedure of choice for most patients’ elderly patients as well as patients with limited dexterity, poor motivation, anatomical restrictions and poor renal function. Studies measuring HRQOL report excellent patient acceptability, especially in the elderly population.
- Open Access
- 28 August 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 412
Comparison of the clonality of urothelial carcinoma developing in the upper urinary tract and those developing in the bladder
Purpose: To identify the origin of synchronous and metachronous urothelial carcinoma (UC) of the bladder and upper urinary tract to get a better understanding of the basic mechanism behind the multifocality of UC, which may provide a sound bases for the future development of new strategies for detection, prevention and therapy. Methods: Six patients with UC of the bladder and synchronous or metachronous UC of the upper urinary tract were studied. Genetic analysis involving the study of loss of heterozygosity (LOH) has been evaluated on their tumours using well characterised and new markers of UC (D9S171, D9S177, D9S303 and TP53). Results: Five of the six patients demonstrated informative results. Four of five (80%) of patients had synchronous or metacharonous UC tumour and showed patterns of LOH consistent with tumorigenesis from monoclonal tumour origin. One of five (20%) patients exhibited a LOH consistent with oligoclonal tumorigenesis. Conclusion: These findings suggest that both the monoclonal and field cancerization theory of tumorigenesis may play a role in tumors of the urothelial tract. However, more data is needed.
- 28 August 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 412
Open AccessComparison of the clonality of urothelial carcinoma developing in the upper urinary tract and those developing in the bladder
Purpose: To identify the origin of synchronous and metachronous urothelial carcinoma (UC) of the bladder and upper urinary tract to get a better understanding of the basic mechanism behind the multifocality of UC, which may provide a sound bases for the future development of new strategies for detection, prevention and therapy. Methods: Six patients with UC of the bladder and synchronous or metachronous UC of the upper urinary tract were studied. Genetic analysis involving the study of loss of heterozygosity (LOH) has been evaluated on their tumours using well characterised and new markers of UC (D9S171, D9S177, D9S303 and TP53). Results: Five of the six patients demonstrated informative results. Four of five (80%) of patients had synchronous or metacharonous UC tumour and showed patterns of LOH consistent with tumorigenesis from monoclonal tumour origin. One of five (20%) patients exhibited a LOH consistent with oligoclonal tumorigenesis. Conclusion: These findings suggest that both the monoclonal and field cancerization theory of tumorigenesis may play a role in tumors of the urothelial tract. However, more data is needed.
- 19 August 2013
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 7 (3) , 190-197
Is postoperative epidural analgesia better than patient-controlled analgesia for radical cystectomy?
The purpose of this study was to evaluate postoperative epidural analgesia (EPA) and intravenous patient-controlled analgesia (PCA) in terms of morbidity and mortality in patients undergoing radical cystectomy for bladder cancer. A retrospective study on patients undergoing radical cystectomy for clinical Tis-4N0M0 urothelial carcinoma of the bladder was performed. Patients were separated into two groups: primary EPA or PCA for postoperative analgesia. The surgical complication severity was determined according to the Clavien system. Mann-Whitney U tests, χ2 with Yates’ correction, or Fisher’s exact test were used. Predictive risk factors were explored using univariable and multivariable Cox regression models. Of the 274 patients studied, 209 (76%) received EPA and 65 (24%) had PCA. Baseline balance was observed. Similar complication rates were observed between the EPA (36%) and PCA (34%) (p=0.382). Patients greater than 70 years of age had more complications (35% vs 21%, p=0.002). PCA patients had higher rates of high-grade complications compared with EPA patients [40% vs 20% (p=0.0007)]. Only age at time of surgery (p=0.032) was associated with complications. Patients with pulmonary disease had a higher risk of complications (p=0.001). EPA or PCA were not predictors for overall survival. There does not appear to be a significant difference in terms of morbidity or mortality between EPA and PCA following radical cystectomy (RC). Rare, catastrophic complications specific to EPA may occur. Standardized reporting of surgical complications is essential to compare studies and appropriately counsel patients.
- 19 August 2013
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 7 (3) , 190-197
Is postoperative epidural analgesia better than patient-controlled analgesia for radical cystectomy?
The purpose of this study was to evaluate postoperative epidural analgesia (EPA) and intravenous patient-controlled analgesia (PCA) in terms of morbidity and mortality in patients undergoing radical cystectomy for bladder cancer. A retrospective study on patients undergoing radical cystectomy for clinical Tis-4N0M0 urothelial carcinoma of the bladder was performed. Patients were separated into two groups: primary EPA or PCA for postoperative analgesia. The surgical complication severity was determined according to the Clavien system. Mann-Whitney U tests, χ2 with Yates’ correction, or Fisher’s exact test were used. Predictive risk factors were explored using univariable and multivariable Cox regression models. Of the 274 patients studied, 209 (76%) received EPA and 65 (24%) had PCA. Baseline balance was observed. Similar complication rates were observed between the EPA (36%) and PCA (34%) (p=0.382). Patients greater than 70 years of age had more complications (35% vs 21%, p=0.002). PCA patients had higher rates of high-grade complications compared with EPA patients [40% vs 20% (p=0.0007)]. Only age at time of surgery (p=0.032) was associated with complications. Patients with pulmonary disease had a higher risk of complications (p=0.001). EPA or PCA were not predictors for overall survival. There does not appear to be a significant difference in terms of morbidity or mortality between EPA and PCA following radical cystectomy (RC). Rare, catastrophic complications specific to EPA may occur. Standardized reporting of surgical complications is essential to compare studies and appropriately counsel patients.
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (6) , 454-8
NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients
Introduction: The nuclear matrix protein 22 (NMP22) assay hasbeen shown to have greater sensitivity for the diagnosis and detectionof recurrent urothelial carcinoma of the bladder (UCB) overthat of traditional urine cytology. We assessed the use of NMP22to predict which high-risk superficial UCB patients will have recurrence,progression or disease-related death; we compared theseresults to standard urine cytology.Methods: One hundred consecutive patients with high-risk superficialUCB were enrolled. During surveillance, urine was collectedfor cytology and NMP22 testing. Patients were followed for atleast 6 months. Retrospective chart review was undertaken to collectdata on previous tumour history, tumour characteristics, diseaserecurrences, progression and death. Kaplan-Meier analyseswere performed to determine the significance between NMP22-positive and -negative patients in terms of recurrence-free, progression-free and overall survival. Similar analyses were performedfor urine cytology.Results: From 94 eligible patients, 15 and 79 were NMP22 positiveand negative, respectively. The baseline characteristics betweenthe 2 groups were not significantly different in terms of patientcharacteristics, prior tumour history or intravesical therapiesreceived. Mean recurrence-free survival time was significantlylower in the NMP22 positive group (p = 0.038); however, meanprogression-free and overall survival were not significantly differentbetween the 2 groups (p = 0.297 and 0.519, respectively).Urine cytology demonstrated no significant predictive power fordisease recurrence, progression or survival.Conclusion: The nuclear matrix protein 22 assay appears to havepredictive value for future tumour recurrences, but not progressionor overall survival in patients with high-risk superficial UCB.Introduction : Il a été montré que le test de dépistage de la protéine22 de la matrice nucléaire (NMP22) présentait une sensibi -lité supérieure pour le diagnostic et le dépistage du carcinomeurothélial récurrent de la vessie, en comparaison avec la cytologieurinaire classique. Nous avons évalué l’emploi de la NMP22pour prédire la récurrence, la progression de la maladie et le décèsrelié à la maladie chez des patients atteints de carcinome urothélialde la vessie (CUV) superficiel et présentant un risque élevé. Lesrésultats ont été comparés à ceux obtenus avec une épreuve decytologie urinaire standard.Méthodologie : Cent patients consécutifs présentant un CUV superficielà risque élevé ont été inscrits à l’étude. Pendant la périodede surveillance, un échantillon d’urine a été recueilli en vue del’épreuve de cytologie et du test de dépistage de la NMP22. Lesuivi a duré au moins 6 mois. Un examen rétrospectif des dossiersa fourni des données concernant les antécédents tumoraux, lescaractéristiques de la tumeur, les récurrences, la progression etles décès. Des analyses de Kaplan-Meier ont été effectuées afinde déterminer le niveau de signification entre les patients NMP22-positifs et négatifs en matière de délai sans récurrence, de délaisans progression et de survie globale. Des analyses similaires ontété réalisées pour les données obtenues par cytologie urinaire.Résultats : Sur les 94 patients admissibles, 15 patients étaientNMP22-positifs et 79, NMP22-négatifs. Les caractéristiques audépart entre les deux groupes n’étaient pas significativement différentesen ce qui concerne les caractéristiques des patients, lesantécédents tumoraux et les antécédents de traitements intravésicaux.Le délai moyen de survie sans récurrence était significativementmoins long dans le groupe de patients NMP22-positifs(p = 0,038); cela dit, le délai moyen sans progression et la survieglobale moyenne n’étaient pas significativement différents entreles deux groupes (p = 0,297 et 0,519, respectivement). L’épreuvede cytologie urinaire n’a montré aucune puissance de prédictionsignificative concernant la récurrence de la maladie, la progressionou la survie.Conclusion : Le test de dépistage de la protéine 22 de la matricenucléaire semble avoir une certaine valeur prédictive concernantles récurrences tumorales, mais non la progression ou la survieglobale chez les patients atteints de CUV superficiel présentantun risque élevé de récurrence.
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (6) , 454-8
NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients
Introduction: The nuclear matrix protein 22 (NMP22) assay hasbeen shown to have greater sensitivity for the diagnosis and detectionof recurrent urothelial carcinoma of the bladder (UCB) overthat of traditional urine cytology. We assessed the use of NMP22to predict which high-risk superficial UCB patients will have recurrence,progression or disease-related death; we compared theseresults to standard urine cytology.Methods: One hundred consecutive patients with high-risk superficialUCB were enrolled. During surveillance, urine was collectedfor cytology and NMP22 testing. Patients were followed for atleast 6 months. Retrospective chart review was undertaken to collectdata on previous tumour history, tumour characteristics, diseaserecurrences, progression and death. Kaplan-Meier analyseswere performed to determine the significance between NMP22-positive and -negative patients in terms of recurrence-free, progression-free and overall survival. Similar analyses were performedfor urine cytology.Results: From 94 eligible patients, 15 and 79 were NMP22 positiveand negative, respectively. The baseline characteristics betweenthe 2 groups were not significantly different in terms of patientcharacteristics, prior tumour history or intravesical therapiesreceived. Mean recurrence-free survival time was significantlylower in the NMP22 positive group (p = 0.038); however, meanprogression-free and overall survival were not significantly differentbetween the 2 groups (p = 0.297 and 0.519, respectively).Urine cytology demonstrated no significant predictive power fordisease recurrence, progression or survival.Conclusion: The nuclear matrix protein 22 assay appears to havepredictive value for future tumour recurrences, but not progressionor overall survival in patients with high-risk superficial UCB.Introduction : Il a été montré que le test de dépistage de la protéine22 de la matrice nucléaire (NMP22) présentait une sensibi -lité supérieure pour le diagnostic et le dépistage du carcinomeurothélial récurrent de la vessie, en comparaison avec la cytologieurinaire classique. Nous avons évalué l’emploi de la NMP22pour prédire la récurrence, la progression de la maladie et le décèsrelié à la maladie chez des patients atteints de carcinome urothélialde la vessie (CUV) superficiel et présentant un risque élevé. Lesrésultats ont été comparés à ceux obtenus avec une épreuve decytologie urinaire standard.Méthodologie : Cent patients consécutifs présentant un CUV superficielà risque élevé ont été inscrits à l’étude. Pendant la périodede surveillance, un échantillon d’urine a été recueilli en vue del’épreuve de cytologie et du test de dépistage de la NMP22. Lesuivi a duré au moins 6 mois. Un examen rétrospectif des dossiersa fourni des données concernant les antécédents tumoraux, lescaractéristiques de la tumeur, les récurrences, la progression etles décès. Des analyses de Kaplan-Meier ont été effectuées afinde déterminer le niveau de signification entre les patients NMP22-positifs et négatifs en matière de délai sans récurrence, de délaisans progression et de survie globale. Des analyses similaires ontété réalisées pour les données obtenues par cytologie urinaire.Résultats : Sur les 94 patients admissibles, 15 patients étaientNMP22-positifs et 79, NMP22-négatifs. Les caractéristiques audépart entre les deux groupes n’étaient pas significativement différentesen ce qui concerne les caractéristiques des patients, lesantécédents tumoraux et les antécédents de traitements intravésicaux.Le délai moyen de survie sans récurrence était significativementmoins long dans le groupe de patients NMP22-positifs(p = 0,038); cela dit, le délai moyen sans progression et la survieglobale moyenne n’étaient pas significativement différents entreles deux groupes (p = 0,297 et 0,519, respectivement). L’épreuvede cytologie urinaire n’a montré aucune puissance de prédictionsignificative concernant la récurrence de la maladie, la progressionou la survie.Conclusion : Le test de dépistage de la protéine 22 de la matricenucléaire semble avoir une certaine valeur prédictive concernantles récurrences tumorales, mais non la progression ou la survieglobale chez les patients atteints de CUV superficiel présentantun risque élevé de récurrence.
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (6-S4) , 193-S198
Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer
Bladder cancer can be classified histologically as urothelial ornon-urothelial. Urothelial cancer has a propensity for divergentdifferentiation, which has increasingly been recognized in recentyears due to heightened awareness and improved immunohistochemistrytechniques. Furthermore, the recent World HealthOrganization classification of urothelial cancers improved clarityon this issue, with its listing of 13 histologic variants of urothelialcancer. The divergent differentiation patterns include, amongstothers, squamous, glandular, micropapillary, nested, lymphepithelioma-like, plasmacytoid and sarcomatoid variants of urothelialcancer. Attempts to quantify the amount of divergent differentiationpresent, such as using the nonconventional differentiationnumber, have been made recently, which will improve the abilityto compare publications from different centres. Genetic-basedstudies have indicated that the histologic variants of urothelialcancer arise from a common clonal precursor. Mostly, the currentevidence suggests that urothelial cancer with divergent differentiationhas a worse prognosis when compared with pure urothelialcancer. This article will review the current literature on varianthistologies of urothelial cancer, and well as new developmentsin pure squamous cell carcinoma, small cell carcinoma and adenocarcinomaof the bladder.
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (6-S4) , 193-S198
Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer
Bladder cancer can be classified histologically as urothelial ornon-urothelial. Urothelial cancer has a propensity for divergentdifferentiation, which has increasingly been recognized in recentyears due to heightened awareness and improved immunohistochemistrytechniques. Furthermore, the recent World HealthOrganization classification of urothelial cancers improved clarityon this issue, with its listing of 13 histologic variants of urothelialcancer. The divergent differentiation patterns include, amongstothers, squamous, glandular, micropapillary, nested, lymphepithelioma-like, plasmacytoid and sarcomatoid variants of urothelialcancer. Attempts to quantify the amount of divergent differentiationpresent, such as using the nonconventional differentiationnumber, have been made recently, which will improve the abilityto compare publications from different centres. Genetic-basedstudies have indicated that the histologic variants of urothelialcancer arise from a common clonal precursor. Mostly, the currentevidence suggests that urothelial cancer with divergent differentiationhas a worse prognosis when compared with pure urothelialcancer. This article will review the current literature on varianthistologies of urothelial cancer, and well as new developmentsin pure squamous cell carcinoma, small cell carcinoma and adenocarcinomaof the bladder.
- 18 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 4 (5) , 126-E132
A rare case of carcinoma cuniculatum of the penis in a 55-year-old
Carcinoma cuniculatum of the penis is an extremely rare variant ofsquamous cell carcinoma characterized by an endophytic deeplybranching and burrowing growth pattern. One documented caseseries demonstrated afflicted patients ranging in age from 73-83years with the tumour located on the glans penis, coronal sulcusor foreskin. We report a case of a 55-year-old with disease locatedon the ventral aspect of the shaft of the penis. The tumour wasinvasive into the deep dermal connective tissue, comparativelysuperficial to all previous documented cases. He subsequentlyunderwent a partial penectomy. The case is discussed with a briefreview of the literature.
- 18 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 4 (5) , 126-E132
A rare case of carcinoma cuniculatum of the penis in a 55-year-old
Carcinoma cuniculatum of the penis is an extremely rare variant ofsquamous cell carcinoma characterized by an endophytic deeplybranching and burrowing growth pattern. One documented caseseries demonstrated afflicted patients ranging in age from 73-83years with the tumour located on the glans penis, coronal sulcusor foreskin. We report a case of a 55-year-old with disease locatedon the ventral aspect of the shaft of the penis. The tumour wasinvasive into the deep dermal connective tissue, comparativelysuperficial to all previous documented cases. He subsequentlyunderwent a partial penectomy. The case is discussed with a briefreview of the literature.
- Open Access
- 16 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 4 (1) , 28-32
Ureteral frozen sections at the time of radical cystectomy: reliability and clinical implications
Background: We hypothesized that the incidence of ureteral abnormalities on frozen section analysis (FS) at the time of radical cystectomy is much lower than historical values and that FS has minimal impact on outcomes. We also sought to determine the accuracy of FS and the associated costs. Methods: We reviewed the records of 301 patients who underwent a radical cystectomy for urothelial carcinoma of the bladder (UC) between March 2000 and January 2007. The ureteral margins were sent for FS and subsequent permanent hematoxyllin and eosin (H&E) sections and results were compared. Analyses were performed to determine the costs of FS and if any association was present with the pathological stage of the primary bladder tumour and regional lymph nodes, the presence of urothelial carcinoma in situ of the bladder (CIS) and survival outcomes with the FS. Results: We identified 602 ureters for this study. The incidence of CIS or solid urothelial carcinoma in the ureter was 2.8%. The presence of CIS of the bladder and prostatic urethra was significantly associated with a positive FS (p = 0.02). The FS were not associated with survival outcomes. The cost to pick up 1 patient with any abnormality on FS was $2080. The cost to pick up 1 patient with CIS or solid urothelial carcinoma of the ureter on FS was $6471. Conclusion: The incidence of CIS and tumour on FS during radical cystectomy for UC is low. The costs associated with FS are substantial. Frozen section analysis should only be performed in select patients undergoing radical cystectomy. Can Urol Assoc J 2010;4(1):28-32 Contexte : Nous avons avancé l’hypothèse que la fréquence des anomalies urétérales notées par analyse de coupes congelées (CC) lors d’une cystectomie radicale est beaucoup plus basse que les valeurs historiques, et que l’analyse des CC a un impact minimal sur l’issue thérapeutique. Nous avons cherché à déterminer l’exactitude de l’analyse des CC et les coûts qui y sont associés. Méthodologie : Nous avons examiné les dossiers de 301 patients ayant subi une cystectomie radicale en raison d’un carcinome urothélial de la vessie entre mars 2000 et janvier 2007. Les marges urétérales avaient été envoyées pour une analyse des CC et une épreuve subséquente de coloration permanente à l’hématoxyline et à l’éosine; les résultats ont ensuite été comparés. Ces analyses ont été menées en vue de déterminer les coûts de l’analyse des CC et de vérifier la présence de tout lien entre les résultats de l’analyse des CC et le stade pathologique de la tumeur vésicale primitive, l’atteinte des ganglions lymphatiques régionaux, la présence d’un carcinome urothélial in situ de la vessie et les taux de survie. Résultats : Nous avons examiné des coupes de 602 uretères pour cette étude. La fréquence de carcinomes urothéliaux in situ ou de carcinomes urothéliaux (tumeurs solides) dans l’uretère était de 2,8 %. La présence d’un carcinome in situ de la vessie et de l’urètre prostatique a été associée de façon significative à des résultats positifs à l’analyse des CC (p = 0.02), mais aucune corrélation n’a été dégagée entre l’analyse des CC et les taux de survie. Les coûts engagés pour cerner un patient présentant une anomalie lors de l’analyse des CC étaient de 2080 $, alors que les coûts engagés pour cerner un patient présentant un carcinome in situ ou un carcinome urothélial solide de l’uretère étaient de 6471 $. Conclusion : L’incidence des carcinomes in situ et des tumeurs solides déterminées par analyse des CC lors d’une cystectomie radicale en raison d’un carcinome urothélial est faible, et les coûts associés à une analyse des CC sont considérables. Une telle analyse des coupes congelées ne devrait donc pas être effectuée pour tous les patients subissant une cystectomie radicale, mais dans certains cas précis seulement.- 16 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 4 (1) , 28-32
Open AccessUreteral frozen sections at the time of radical cystectomy: reliability and clinical implications
Background: We hypothesized that the incidence of ureteral abnormalities on frozen section analysis (FS) at the time of radical cystectomy is much lower than historical values and that FS has minimal impact on outcomes. We also sought to determine the accuracy of FS and the associated costs. Methods: We reviewed the records of 301 patients who underwent a radical cystectomy for urothelial carcinoma of the bladder (UC) between March 2000 and January 2007. The ureteral margins were sent for FS and subsequent permanent hematoxyllin and eosin (H&E) sections and results were compared. Analyses were performed to determine the costs of FS and if any association was present with the pathological stage of the primary bladder tumour and regional lymph nodes, the presence of urothelial carcinoma in situ of the bladder (CIS) and survival outcomes with the FS. Results: We identified 602 ureters for this study. The incidence of CIS or solid urothelial carcinoma in the ureter was 2.8%. The presence of CIS of the bladder and prostatic urethra was significantly associated with a positive FS (p = 0.02). The FS were not associated with survival outcomes. The cost to pick up 1 patient with any abnormality on FS was $2080. The cost to pick up 1 patient with CIS or solid urothelial carcinoma of the ureter on FS was $6471. Conclusion: The incidence of CIS and tumour on FS during radical cystectomy for UC is low. The costs associated with FS are substantial. Frozen section analysis should only be performed in select patients undergoing radical cystectomy. Can Urol Assoc J 2010;4(1):28-32 Contexte : Nous avons avancé l’hypothèse que la fréquence des anomalies urétérales notées par analyse de coupes congelées (CC) lors d’une cystectomie radicale est beaucoup plus basse que les valeurs historiques, et que l’analyse des CC a un impact minimal sur l’issue thérapeutique. Nous avons cherché à déterminer l’exactitude de l’analyse des CC et les coûts qui y sont associés. Méthodologie : Nous avons examiné les dossiers de 301 patients ayant subi une cystectomie radicale en raison d’un carcinome urothélial de la vessie entre mars 2000 et janvier 2007. Les marges urétérales avaient été envoyées pour une analyse des CC et une épreuve subséquente de coloration permanente à l’hématoxyline et à l’éosine; les résultats ont ensuite été comparés. Ces analyses ont été menées en vue de déterminer les coûts de l’analyse des CC et de vérifier la présence de tout lien entre les résultats de l’analyse des CC et le stade pathologique de la tumeur vésicale primitive, l’atteinte des ganglions lymphatiques régionaux, la présence d’un carcinome urothélial in situ de la vessie et les taux de survie. Résultats : Nous avons examiné des coupes de 602 uretères pour cette étude. La fréquence de carcinomes urothéliaux in situ ou de carcinomes urothéliaux (tumeurs solides) dans l’uretère était de 2,8 %. La présence d’un carcinome in situ de la vessie et de l’urètre prostatique a été associée de façon significative à des résultats positifs à l’analyse des CC (p = 0.02), mais aucune corrélation n’a été dégagée entre l’analyse des CC et les taux de survie. Les coûts engagés pour cerner un patient présentant une anomalie lors de l’analyse des CC étaient de 2080 $, alors que les coûts engagés pour cerner un patient présentant un carcinome in situ ou un carcinome urothélial solide de l’uretère étaient de 6471 $. Conclusion : L’incidence des carcinomes in situ et des tumeurs solides déterminées par analyse des CC lors d’une cystectomie radicale en raison d’un carcinome urothélial est faible, et les coûts associés à une analyse des CC sont considérables. Une telle analyse des coupes congelées ne devrait donc pas être effectuée pour tous les patients subissant une cystectomie radicale, mais dans certains cas précis seulement. - 15 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 5 (6) , 148-151
How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes?
Introduction: Surgical wait times have been shown to be of significancein other malignancies, but limited studies exist in renalcell cancer (RCC). We analyzed surgical waiting time for RCCpatients to see if there was an adverse impact on pathologicalcharacteristics.Methods: Our centre triages RCC patients on the basis of perceivedtumour risk. The waiting time for surgery is adjusted stage for stage:clinical T1 at 90 days, T2 at 40 days, T3 and T4 at 30 days. Weretrospectively reviewed the charts of 354 patients who underwentsurgery for RCC. Patients were assessed for pathological upstaging,positive lymph nodes, tumour recurrence and tumour size withineach stage. Analysis was performed, using surgical waiting time asa categorical variable, to test for associations with disease recurrenceor adverse pathological characteristics.Results: The median time from the first consultation to surgery was41 days and the mean follow-up was 26.6 months. Waiting timestage for stage was: clinical T1 at 57.12 days, clinical T2 at 36.8days, clinical T3 and T4 at 30.32 days. On multivariate analysis,pathological tumour size was associated with progression, whereasno significant association was found between waiting time andupstaging. Higher stage tumours, sarcomatoid pathology and clinicalevidence of progression were associated with shorter waitingtimes for early interventions.Conclusions: There was no statistically significant evidence forupstaging or progression during the waiting period for our groupof patients. The data reinforce previous studies reporting a “safe”period of active surveillance in T1 RCC without affecting their finalpathological outcome.Introduction : Il a été montré que les temps d’attente en chirurgieont de l’importance avec d’autres tumeurs malignes, mais il existepeu d’études concernant l’hypernéphrome. Nous avons analysé letemps d’attente avant une intervention chirurgicale des patientsatteints d’hypernéphrome pour voir si ce temps d’attente avait uneffet négatif sur les caractéristiques pathologiques.Méthodes : Notre centre trie les patients atteints d’hypernéphromesur la base du risque perçu lié à la tumeur. Le temps d’attente pourla chirurgie est ajusté en fonction du stade : stade clinique T1, 90jours, stade T2, 40 jours, stades T3 et T4, 30 jours. Nous avonsexaminé de façon rétrospective les dossiers de 354 patients ayantsubi une chirurgie pour traiter un hypernéphrome. Les patients ontété évalués pour cerner la présence d’une progression du stadepathologique ou de ganglions lymphatiques positifs, et la récidiveet la taille de la tumeur pour chaque stade. L’analyse a été effectuéeen utilisant le temps d’attente avant l’intervention comme variablecatégorique, afin de vérifier son lien avec la récurrence de la maladieou des caractéristiques pathologiques néfastes.Résultats : Le délai médian entre la première consultationet l’intervention était de 41 jours, et le suivi moyen était de26,6 mois. Le temps d’attente en fonction du stade allait commesuit : stade clinique T1, 57,12 jours, stade clinique T2, 36,8 jours,stades cliniques T3 et T4, 30,32 jours. Lors de l’analyse multivariée,une corrélation a été établie entre la taille de la tumeuret la progression, alors qu’aucun lien significatif n’a été observéentre les temps d’attente et la progression du stade pathologique.Un stade tumoral supérieur, des caractéristiques sarcomatoïdes àl’examen pathologique et des preuves cliniques de progression ontété associés à des temps d’attente plus courts pour les interventionsprécoces.Conclusions : Il n’y avait aucune donnée statistiquement significativemontrant une progression du stade pathologique au cours dela période d’attente pour notre groupe de patients. Les donnéesconfirment les résultats d’études antérieures signalant une période «sans danger » de surveillance active dans les cas d’hypernéphromede stade T1 sans que cela n’affecte le résultat pathologique final.
- 15 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 5 (6) , 148-151
How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes?
Introduction: Surgical wait times have been shown to be of significancein other malignancies, but limited studies exist in renalcell cancer (RCC). We analyzed surgical waiting time for RCCpatients to see if there was an adverse impact on pathologicalcharacteristics.Methods: Our centre triages RCC patients on the basis of perceivedtumour risk. The waiting time for surgery is adjusted stage for stage:clinical T1 at 90 days, T2 at 40 days, T3 and T4 at 30 days. Weretrospectively reviewed the charts of 354 patients who underwentsurgery for RCC. Patients were assessed for pathological upstaging,positive lymph nodes, tumour recurrence and tumour size withineach stage. Analysis was performed, using surgical waiting time asa categorical variable, to test for associations with disease recurrenceor adverse pathological characteristics.Results: The median time from the first consultation to surgery was41 days and the mean follow-up was 26.6 months. Waiting timestage for stage was: clinical T1 at 57.12 days, clinical T2 at 36.8days, clinical T3 and T4 at 30.32 days. On multivariate analysis,pathological tumour size was associated with progression, whereasno significant association was found between waiting time andupstaging. Higher stage tumours, sarcomatoid pathology and clinicalevidence of progression were associated with shorter waitingtimes for early interventions.Conclusions: There was no statistically significant evidence forupstaging or progression during the waiting period for our groupof patients. The data reinforce previous studies reporting a “safe”period of active surveillance in T1 RCC without affecting their finalpathological outcome.Introduction : Il a été montré que les temps d’attente en chirurgieont de l’importance avec d’autres tumeurs malignes, mais il existepeu d’études concernant l’hypernéphrome. Nous avons analysé letemps d’attente avant une intervention chirurgicale des patientsatteints d’hypernéphrome pour voir si ce temps d’attente avait uneffet négatif sur les caractéristiques pathologiques.Méthodes : Notre centre trie les patients atteints d’hypernéphromesur la base du risque perçu lié à la tumeur. Le temps d’attente pourla chirurgie est ajusté en fonction du stade : stade clinique T1, 90jours, stade T2, 40 jours, stades T3 et T4, 30 jours. Nous avonsexaminé de façon rétrospective les dossiers de 354 patients ayantsubi une chirurgie pour traiter un hypernéphrome. Les patients ontété évalués pour cerner la présence d’une progression du stadepathologique ou de ganglions lymphatiques positifs, et la récidiveet la taille de la tumeur pour chaque stade. L’analyse a été effectuéeen utilisant le temps d’attente avant l’intervention comme variablecatégorique, afin de vérifier son lien avec la récurrence de la maladieou des caractéristiques pathologiques néfastes.Résultats : Le délai médian entre la première consultationet l’intervention était de 41 jours, et le suivi moyen était de26,6 mois. Le temps d’attente en fonction du stade allait commesuit : stade clinique T1, 57,12 jours, stade clinique T2, 36,8 jours,stades cliniques T3 et T4, 30,32 jours. Lors de l’analyse multivariée,une corrélation a été établie entre la taille de la tumeuret la progression, alors qu’aucun lien significatif n’a été observéentre les temps d’attente et la progression du stade pathologique.Un stade tumoral supérieur, des caractéristiques sarcomatoïdes àl’examen pathologique et des preuves cliniques de progression ontété associés à des temps d’attente plus courts pour les interventionsprécoces.Conclusions : Il n’y avait aucune donnée statistiquement significativemontrant une progression du stade pathologique au cours dela période d’attente pour notre groupe de patients. Les donnéesconfirment les résultats d’études antérieures signalant une période «sans danger » de surveillance active dans les cas d’hypernéphromede stade T1 sans que cela n’affecte le résultat pathologique final.